TRADEUP ACQUISITION CORP-CW (ESLAW:NASDAQ)

$0.0701 0.0001 (0.1429%)

watchlist-icon
search-icon
Profile Icon

Most Recent Average Sentiment Analysis Score (0 to 100): 81

negative-sentiment
Negative [0, 35)
neutral-sentiment
Neutral [35, 65]
positive-sentiment
Positive (65, 100]
Visualize Sentiment Trendline

Analysed TRADEUP ACQUISITION CORP-CW (ESLAW:NASDAQ) News Sources

ESLA: Initiating Coverage of Estrella Immunopharma: A Potential Successor to Arcellx in Next-Generation CAR-T

18-03-2026

yahoo.com

ESLA: Can Next-Generation CAR-T Therapy Improve Disease Control in Extranodal Lymphoma?

14-07-2026

yahoo.com

Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin’s Lymphoma

24-07-2026

yahoo.com

Estrella Immunopharma Activates Baylor Scott & White Research Institute as Second Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

29-07-2026

yahoo.com

Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

03-08-2026

yahoo.com

Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

11-08-2026

yahoo.com

ESLA: First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial

26-08-2026

yahoo.com

Estrella Immunopharma Activates Intermountain Health LDS Hospital as Fifth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

14-10-2026

yahoo.com

Estrella Immunopharma Treats First Patient with Two EB103 Infusions in STARLIGHT-1 Dose-Expansion Phase

15-10-2026

yahoo.com

Estrella Immunopharma Appoints Cynthia Pussinen as Chief Executive Officer and Chairperson of the Board of Directors

26-10-2026

yahoo.com

TRADEUP ACQUISITION CORP-CW (ESLAW:NASDAQ) Sentiment Trend

0 25 50 75 100 88 78 84 79 80 82 88 82 81 67 18-03-2026 14-07-2026 24-07-2026 29-07-2026 03-08-2026 11-08-2026 26-08-2026 14-10-2026 15-10-2026 26-10-2026 #1 #2 #3 #4 #5 #6 #7 #8 #9 #10 Negative < 35 Neutral 35–65 Positive > 65 View FAQ

TRADEUP ACQUISITION CORP-CW (ESLAW:NASDAQ) FAQs

toggle

What is the current price of TRADEUP ACQUISITION CORP-CW (ESLAW:NASDAQ)?

The current price of TRADEUP ACQUISITION CORP-CW (ESLAW:NASDAQ) is $0.0701.


toggle

TRADEUP ACQUISITION CORP-CW (ESLAW:NASDAQ) absolute price change since previous trading day?

The absolute price change of TRADEUP ACQUISITION CORP-CW (ESLAW:NASDAQ) since the previous trading day is $0.0001.


toggle

TRADEUP ACQUISITION CORP-CW (ESLAW:NASDAQ) percentage price change since previous trading day?

The percentage price change of TRADEUP ACQUISITION CORP-CW (ESLAW:NASDAQ) since the previous trading day is 0.1429%.


toggle

What is the most recent average sentiment score for TRADEUP ACQUISITION CORP-CW (ESLAW:NASDAQ)?

The most recent average sentiment score for TRADEUP ACQUISITION CORP-CW (ESLAW:NASDAQ) is 81 out of 100.


toggle

What is the most recent average sentiment for TRADEUP ACQUISITION CORP-CW (ESLAW:NASDAQ)?

The most recent sentiment for TRADEUP ACQUISITION CORP-CW (ESLAW:NASDAQ) is .


SEC-8K** Filing Available For TRADEUP ACQUISITION CORP-CW (ESLAW:NASDAQ)

** material developments that could impact a company's financial condition or stock price.

Author: MattELab

X Icon

GitHub Icon

MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.